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Main text
Colorectal cancer (CRC) is the third most frequent can-
cer type worldwide [1] and distant metastasis represents 
its most lethal attribute. About every second CRC patient 
develops distant metastasis [2, 3] and about 30% as peri-
toneal metastasis (pmCRC) [4] associated with inferior 
outcome and limited treatment opportunities [5, 6]. This 
defines an urgent need for applied translational research 
to identify and exploit new biomarkers, signatures, and 
molecular targets for personalized pmCRC treatment 
with well-characterized pre-clinical disease models.
Here we report newly established matched PDX and 
PD3D pmCRC models as molecularly characterized 
platform for pre-clinical and co-clinical evaluation of 
treatment response and identification of predictive bio-
markers (Fig.  1A). We received 57 surgical specimens 
from 37 pmCRC patients and established 14 pmCRC 
PDX models from 10 patients (see Table S1). Nine PDX 
models were derived from pmCRC at the peritoneum 
and five from the omentum, with four model pairs from 
both sites of the same patient. The mean tumor doubling 
time of the PDX models was 10.9 ± 6.2 d, ranging from 
4.2 d to 28.4 d, with significantly different growth rates 
for two PDX pairs (Fig.  S1A). Histological comparison 
of patient metastases with corresponding PDX tumors 
revealed similar features of adenocarcinoma (Fig.  1B). 
Further, PDX tumors were positive for human nuclei 
antibody staining, leaving surrounding stroma negative. 
This indicates replacement of human by murine stroma 
during in vivo passaging (Fig. 1C). The majority of PDX 
tumors contained about 5% to 15% murine stroma, while 
two models showed up to 40% mouse stroma (Table S6). 
To generate matched PD3D models, 13 PDX tumors have 
been explanted and processed, as described by Schütte 
et al. [7], succeeding in establishing nine pmCRC PD3D 
models.
PDX and PD3D models were treated with standard-of-
care (SoC) and targeted drugs with individual concentra-
tions and application schemes (Table  S2). Within PDX 
models, irinotecan showed best response for SoC drugs, 
while MEK inhibition (trametinib, selumetinib) showed 
best response for targeted treatment (Fig. 1D; Fig. S1B,C; 
Table  S3). Interestingly, only one model showed treat-
ment response to both trametinib and selumetinib, even 
within models from the same patient, possibly reflecting 
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their individual modes of action in MEK1 inhibition 
[8]. Similarly, 5-FU and SN38 treatment, respectively, 
resulted in robust growth inhibition of PD3D models, 
while best efficacy among targeted drugs was observed 
for PI3K and MEK inhibition (Fig.  1E; Tables  S4,S5). 
By plotting the categorized responses for each drug, 
we observed 76 ± 20% of all matched PDX/PD3D mod-
els distributed in a range of moderate to high concord-
ance (Fig.  1F). Highest number of concordant response 
of matched PDX/PD3D models to SoC treatment was 
observed for oxaliplatin (n = 8), followed by cetuximab, 
regorafenib and erlotinib (n  = 7, each). Least response 
concordance was observed with irinotecan/SN38 (n = 5) 
and although the response of the PD3D cell culture mod-
els correlates with the expression pattern of SLCO1B3 as 
a SN83 transporter [9] and UGT1A1, which catalyzes the 
glucuronylation of SN38 [10], a molecular mechanism of 
the observed response discordance needs to be validated. 
In opposite, some targeted drugs showed poor response 
rates in both PDX and PD3D models, but with high con-
cordance, which was verified by low respective pathway 
activity (Fig. S3A). Least concordance of PDX and PD3D 
model response to targeted drugs was observed for 
copanlisib (n = 2), which indicates altered PI3K signaling 
activity, bypassing or crosstalk of other signaling path-
ways within the respective model type. Taken together, 
although we observed rather discordant responses in the 
pmCRC models in some cases of treatment, the genera-
tion of matched preclinical models in general can identify 
best model types for response evaluation of individual 
therapies.
In general, by generating preclinical models, mainly 
human tumor cells are maintained in the PDX tumors 
and PD3D cell culture, which certainly undergo adap-
tation to their respective environment (in vitro culture 
or mouse), but maintain key molecular characteristics 
and sensitivity profiles. This is accompanied by the lack 
of transcripts specific for human tumor stroma in these 
samples. Although tumor stroma cells, and immune 
cells in particular, of patient tissues have an emerging 
prognostic and predictive value, they only marginally 
contribute to the treatment response in the established 
preclinical models. For identification of novel predic-
tive biomarkers in pmCRC for SoC and targeted drug 
treatments we molecularly characterized the original 
patient pmCRC and corresponding PDX/PD3D mod-
els by RNAseq and patient-derived pmCRC models 
also by mass-spectrometry proteomics and phospho-
proteomics. Transcript expression patterns and known 
polymorphisms correlated highly between matched 
patient metastases and PDX, but also between matched 
PDX/PD3D models, similarly to protein expression and 
phosphorylation (Fig.  2A; Fig.  S2C-F). Classifying the 
biological features of pmCRC by predicting the con-
sensus molecular subtype (CMS), which also impacts 
treatment decisions [11], resulted in subtype 4 for the 
majority of patient samples (Table S1). CMS 4 is char-
acterized by a mesenchymal phenotype that reflects the 
predominant therapy resistance with partial response 
to irinotecan [12]. The analysis of genetic alterations 
commonly occurring in CRC confirmed the clinically 
determined KRAS-G12/13 mutation status of patients 
(Table  S1), but also detected an additional pathogenic 
KRAS-Q61K mutation. Observed pathogenic muta-
tions of APC, p53, SMAD4, RNF43, GNAS and EP300 
are mainly maintained in the derived models (Fig.  2B, 
Table S7) and are similar to previously reported muta-
tion rates for metastasized CRC (Table  S9) [13, 14]. 
According to tumor heterogeneity, enrichment or 
loss of individual tumor cell types during model gen-
eration, some occurring cancer-related mutations were 
not detected in every sample of the respective model. 
For clinical application, relevant mutations in patient 
metastases should then be detected at higher preci-
sion, e.g. by targeted sequencing. Of note, we observed 
an unexpected high number of frameshift mutations 
in BRCA2 and further genes related to DNA damage 
repair, like ATM, ATR and CDK12 among the pmCRC 
Fig. 1 Matched pmCRC models retain histopathological tumor features and are suitable to determine therapeutic response. A Schematic 
representation of the project to generate a preclinical platform of matched pmCRC PDX/PD3D models for evaluating treatment response and 
predictive biomarker signatures. B PDX tumors retain histopathological features of the original human metastastic tissue, determined by H&E 
staining and KRT19 immunohistochemistry. C Human tumor stroma in pmCRC PDX models is replaced by mouse stroma during passaging, 
determined by immunofluorescence. D Treatment response of pmCRC PDX models (n = 14). Treatment of PDX models was started at palpable 
tumors (0.1  cm3) and the ratio of the mean TV of the treated group (T) and the solvent treated control group (C) was expressed as the T/C‑value in 
percent. E Treatment response of pmCRC PD3D cell cultures (n = 9) as viability at highest plasma concentration  (Cmax) of each tested compound. 
Whiskers and outliers are plotted according to Tukey. F Bubble plot representation of categorized treatment response of 9 matched pmCRC PDX 
and PD3D models (T/C and viability at  Cmax, respectively) for treatment with SoC and targeted drugs. The shading of the fields indicates the degree 
of concordance in response, the color of each circle represents individual drugs and the size of each circle corresponds with the number of models 
in the same category. T/C‑values for PDX models were categorized as strong response (0–10%), moderate response (11–25%), minor response 
(26–50%) and resistant (> 50%). Similarly, viability of PD3D cell cultures at  Cmax was categorized as strong response (0–30%), moderate response 
(31–60%), minor response (61–80%) and resistant (> 80%)
(See figure on next page.)
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samples (Fig.  2B; Tables  S7, S8 and S9), compared to 
the much lower rate of BRCA1/2 mutations in MSS 
CRC (< 2%), which can rise to > 20% in MSI-H CRC 
[13]. As BRCA1/2 mutations are only marginally asso-
ciated with successful PDX engraftment [15] and their 
mutation status is preserved from patient tissue over 
several PDX passages [16] we do not assume a biased 
model generation. Nevertheless, our findings strongly 
support further studies about the use of PARP inhibi-
tors as treatment for pmCRC with the identified bio-
marker profile. In turn, analyzing the transcriptomes 
of patient metastases and derived models according 
to cancer hallmark gene signatures (including DNA 
repair in general), showed similar patterns of gene 
set enrichments at transcriptome and proteome level 
(Fig.  S3A,B). When focusing on cellular DNA repair 
mechanisms in more detail, we observed clustering of 
patient metastases according to their predicted DNA 
repair activity (Fig.  2C). This was reflected in tran-
scriptomic and proteomic analyses of PDX and PD3D 
models (Fig.  S4A,B). This pattern was again observed 
when all sample types were predicted for their response 
to selected PARP inhibitors (Fig.  2D, Fig.  S5A,B). The 
enrichment of DNA damage repair pathways in indi-
vidual samples was analyzed in more detail by select-
ing pathway-specific gene sets for base and nucleotide 
excision repair, homologous recombination and Fan-
coni anemia [17] (Fig.  S6A,B). Furthermore, gene set 
enrichment analysis (GSEA) of combined PDX mod-
els showing treatment response to 5-FU versus resist-
ant models resulted in significantly enriched gene sets 
indicating DNA repair (ES = 0.44, p  = 0.009), specifi-
cally NER (ES = 0.42, p = 0.002), and response to veli-
parib (ES = 0.62, p < 0.001; Fig. 2F, Fig. S7A). Similarly, 
PDX models resistant to selumetinib treatment showed 
enriched gene signatures for BER (ES = 0.57, p = 0.016), 
Fanconi anemia pathway (ES = 0.46, p  = 0.061) and 
veliparib response (ES = 0.51, p  = 0.004; Fig.  S7B). 
Metascape and Kinase Enrichment Analysis [18, 19] 
were used to analyze integrated proteomic and phos-
phoproteomic data of grouped resistant and respon-
sive models. Differential 5-FU response of PDX models 
was mainly characterized by altered α6/β4 signaling 
(Fig. S7C), with differential activity of PKC, PTK2/FAK 
and FYN (Fig.  2F, Fig.  S4C, Fig.  S7D,E). PTK2/FAK 
signaling has been recently connected to DNA dam-
age response regulation [20]. Phospho-ɣ-H2AX, as an 
indicator of DNA double-strand breaks [21], has been 
found significantly less abundant in 5-FU resistant PDX 
models  (log2FC = − 1.91, p = 0.002). As PARP activity 
is found in virtually all DNA repair mechanisms [22], 
its inhibition in tumor cells with a deficiency in homol-
ogous recombination (e.g. mutated BRCA1/2) leads to 
cell death and besides its clinical use in treating ovarian 
and breast cancer, it is also evaluated for gastrointes-
tinal tumors [23–25]. Recent reports demonstrate the 
synergistic effect of combining PARP inhibitors with 
5-FU in CRC treatment [26, 27]. Similarly, combined 
inhibition of PARP and MEK represents a promising 
rationale for novel anti-cancer therapy [28], which is 
already tested in a clinical phase I trial (NCT03162627). 
For response analysis of combination treatment of the 
PARP inhibitor olaparib with either 5-FU or trametinib 
in  vitro, we selected pmCRC models according to the 
list of identified predictive biomarkers (Table S12) and 
employed different approaches: first we used single cell 
suspensions of PDX tumor tissues, applied a drug con-
centration matrix (Fig. 2G) and measured cell cytotox-
icity over time. Indeed, we found a synergistic effect of 
both 5-FU and trametinib treatment in combination 
(See figure on next page.)
Fig. 2 Multi‑omics characterization of pmCRC metastases, PDX tumors and PD3D models confirms similarity of matched pmCRC models and 
can be used for predictive biomarker analysis. A Box plot representation of Pearson correlation coefficients of matched models on the basis of 
transcriptome, proteome and phosphoproteome analysis of patient metastases, PDX tumors and PD3D cell culture models. Center lines show the 
medians; box limits and whiskers are plotted according to Tukey, outliers are represented by dots. B Representation of the occurrence of frameshift 
mutations, truncations or amino acid substitutions commonly found in CRC. Respective gene mutations were counted when they were found in 
the patient metastasis or enriched in the generated PDX or PD3D models. Black – pathogenic according to ClinVar, dark grey – non‑pathogenic/
uncertain according to ClinVar, light grey – no alteration to reference sequence. C Single sample gene set enrichment analysis (ssGSEA) of 
expressed transcripts of patient metastases focusing on DNA repair signatures (MsigDB/Reactome). D Prediction of treatment response to PARP 
inhibitors 3‑aminobenzamide, olaparib and veliparib by ssGSEA of drug response signatures (DsigDB) of expressed transcripts. E GSEA of PDX 
tumor expression signatures grouped for response or resistance to 5‑FU treatment. Significant enrichments were found for DNA repair in general 
(MsigDB/Hallmarks) and the signature for response to veliparib treatment (DsigDB). F Visualization of altered kinase activity and interaction (KEA3) 
by integrated proteome and phosphoproteome data of 5‑FU responsive and resistant PDX models. Blue – present in top‑10 of either MeanRank 
or TopRank score, orange – present in both top‑25 of both MeanRank and TopRank score. G,H Response evaluation of pre‑clinical pmCRC 
models under combinatorial treatment of 5‑FU or trametinib with olaparib. Explanted PDX tumor cells (G) were treated with the indicated drug 
concentration and combination for 24 h in the presence of a fluorescent cytotoxicity marker. Fluorescence signals of each treatment condition, 
indicating dead or dying cells, were normalized to the cell confluence of the same well (n = 2). Blue – decreased cytotoxicity compared to median, 
red – increased cytotoxicity compared to median. PD3D cell culture models (H) were treated with  Cmax concentrations of 5‑FU, trametinib, olaparib 
or drug combinations and treatment response was determined as cell viability after 4 days (n = 4)
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with olaparib in resistant models, compared to models 
that already responded well to the individual drug alone 
(Fig.  2G, Fig.  S8A-D, Table  S12). Second, treatment 
of PD3D models was performed similarly and con-
firmed the improved response to combination therapy 
of 5-FU or trametinib with olaparib (Fig. 2H, Fig. S8E, 
Table S12).
Analysis of further factors, such as age, sex, locali-
zation of the primary CRC (left/right colon), the 
localization of the peritoneal metastasis (peritoneum/
omentum) or its histopathology (mucinous/non-muci-
nous adenocarcinoma) for treatment response to the 
tested SoC and targeted drugs, revealed no statistically 
significant predictive impact.
In summary, together with DNA repair deficiency 
promising novel predictive biomarkers were identified 
by molecular characterization of the pmCRC mod-
els, mainly analyzing differential gene expression of 
responders and non-responders for each drug treat-
ment. Sensitivity and specificity of response prediction 
using ROC-based cut-off values for PDX and patient 
metastases resulted in matching biomarkers for the 
respective treatment response (Table S10), similarly to 
potentially predicting transcript variants (Table  S11), 
ready to be included in prospective studies.
Conclusion
This study reports for the first time the establishment of 
matched PDX/PD3D models from pmCRC, including 
thorough molecular characterization by multi-omics. 
Predictive biomarkers were identified for pmCRC to 
facilitate treatment selection for improved outcome. 
One of the novel key finding is the high occurrence of 
mutation in genes encoding for homologous recombi-
nation enzymes in almost all analyzed pmCRC patient 
samples, but activated alternative DNA repair mecha-
nisms in samples resistant to 5-FU or MEK inhibitors. 
Pre-clinical pmCRC models resistant to the individual 
5-FU or trametinib monotherapy showed an improved 
response in combination therapy with olaparib. This 
encourages the evaluation of PARP inhibitors, either as 
monotherapy in pmCRC or in combination with DNA 
damage-inducing drugs or MEK inhibition, for more 
effective pmCRC treatment. Thus, our pmCRC mod-
els are not only of value for advanced prognosis but 
also for tailoring therapies based on molecular char-
acteristics of pmCRC as new momentum for clinical 
translation.
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Additional file 1: Figure S1. Growth and treatment response of pmCRC 
PDX models. A) Tumor doubling time of untreated pmCRC PDX models 
was assessed by volumetric measurement of the tumor growth in two 
dimensions with a caliper. Tumor volumes (TV) were determined by 
the formula: TV =  (width2 x length) × 0.5, and show variances between 
models of the same patient, but different localization (n = 3). Bold – CRC 
metastasis localized at the peritoneum, regular – CRC metastasis localized 
at the omentum. B‑C) Treatment response of pmCRC PDX models to 
individual SoC (B) and selected targeted drugs (C).
Additional file 2: Figure S2. Growth and treatment response of pmCRC 
PD3D models and high correlation of molecular characteristics indicate 
high similarity of each generated pair of matched pmCRC PDX and PD3D 
cell culture models. A) Representative images showing the effect of the 
tested compounds on the size and morphology of PDX‑derived PD3Ds 
(exemplified by CRC‑21). Scale bar = 100 μm, B) Dose‑response fitted 
curves showing cell viability after 4 days (n = 4) of the different PD3D 
models for each compound tested. Dotted lines show the maximum 
human plasma concentration of each tested drug  (Cmax). C‑F) Distributions 
of Pearson and Spearman correlation values, comparing pmCRC metasta‑
ses (red bars), PDX tumors (green bars) and PD3D cell culture models (blue 
bars) after transcriptomic (C,D), proteomic (E) and phosphoproteomic (F) 
analysis.
Additional file 3: Figure S3. Single sample gene set analysis (ssGSEA) 
confirms similarity of pmCRC patient metastases and derived matched 
models in predicted activity of cancer‑related cellular processes. A) Tran‑
scriptomic single sample enrichment analysis of cancer hallmark gene sets 
of pmCRC metastases, PDX tumors and PD3D culture cell models. B) Prot‑
eomic single sample enrichment analysis for cancer hallmark signatures of 
pmCRC PDX tumor and PD3D cell culture models.
Additional file 4: Figure S4. Patient samples and derived pre‑clinical 
models are similar in their predicted activity of cellular DNA repair mecha‑
nisms and signaling pathways. A) Transcriptomic single sample enrich‑
ment analysis of reactome gene sets related to DNA repair of pmCRC 
metastases, PDX tumors and PD3D culture cell models. B) Proteomic 
single sample enrichment analysis for DNA repair signatures of pmCRC 
PDX tumor and PD3D cell culture models. C) Single sample enrichment 
analysis of phosphoproteomic signaling pathway signatures. PSP – Phos‑
phoSitePlus, P100 – PanoramaWeb/LINCS, NP – NetPath.
Additional file 5: Figure S5. Single sample gene set analysis confirms 
similarity of pmCRC patient metastases and derived matched models in 
predicted response to anti‑cancer drugs. A) Transcriptomic single sample 
enrichment analysis of signatures predicting treatment response to 
selected anti‑cancer drugs of pmCRC metastases, PDX tumors and PD3D 
culture cell models. B) Proteomic single sample enrichment analysis for 
drug response signatures of pmCRC PDX tumor and PD3D cell culture 
models.
Additional file 6: Figure S6. Pathway‑specific gene sets reveal less active 
DNA damage repair pathways in pmCRC patient samples compared to 
preclinical models. A,B) Transcriptomic single sample enrichment analysis 
of pathway‑specific gene sets predicting the activity of individual DNA 
damage repair pathways (A) and the expression distribution of pathway‑
specific gene expression (B). Pat – pmCRC patient metastases.
Additional file 7: Figure S7. Integrated analysis of altered signatures 
of cellular processes, signaling pathway and kinase activity in treatment 
resistant and responsive PDX models. A,B) GSEA of PDX tumor transcript 
expression signatures grouped for response or resistance to 5‑FU (A) 
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and selumetinib (B) treatment. Significant enrichments were found for 
DNA repair in general (MsigDB/Hallmarks), nucleotide and base excision 
repair, as well as Fanconi anemia (MsigDB/Reactome) and the signature 
for response to veliparib treatment (DsigDB). C) Visualization of altered 
cellular processes (Metascape) according to integrated proteome and 
phosphoproteome data of 5‑FU responsive and resistant PDX models. D,E) 
Integrated proteome and phosphoproteome data analysis (KEA3) of 5‑FU 
resistant (D) and responsive (E) PDX models for altered kinase activity and 
visualization of interaction networks. Left panels list the top‑10 kinases 
according to their sum of ranks (MeanRank score), with colors indicat‑
ing the scores used from external sources. Middle panels list the top‑10 
kinases according to their TopRank score. Right panels visualize the inter‑
action networks of top scoring kinases for each analysis. Blue – present 
in top‑10 of either MeanRank or TopRank score, orange – present in both 
top‑25 of both MeanRank and TopRank score.
Additional file 8: Figure S8. Combinatorial treatment of PDX tumor 
explants and PD3D cell culture models improves treatment response for 
models resistant to monotherapy. A‑D) Response evaluation of responsive 
(A,B) and resistant (C,D) pmCRC PDX models under combinatorial treat‑
ment of 5‑FU (A,C) or trametinib (B,D) with olaparib. Explanted PDX tumor 
cells were treated with the indicated drug concentration and combination 
for 24 h in the presence of a fluorescent cytotoxicity marker. Fluorescence 
signals of each treatment condition (n = 2) indicating dead or dying cells 
were normalized to the respective cell confluence. Blue – decreased 
cytotoxicity compared to median; red – increased cytotoxicity compared 
to median. E) PD3D cell culture models were treated with  Cmax concentra‑
tions of 5‑FU, trametinib, olaparib, or their combinations, and response 
was determined as cell viability after 4 days (n = 4).
Additional file 9: Table S1. pmCRC patient cohort characteristics. 
Table S2. Compound concentrations and application for preclinical 
treatment. Table S3. PDX treatment response (T/C). Table S4. PD3D 
treatment response (viability at  Cmax). Table S5. PD3D treatment response 
 (IC50). Table S6. Ratios and correlations of pmCRC sample types. Table S7. 
Comparison of identified CRC‑related polymorphisms in the transcrip‑
tome of patient metastases and derived models. Table S8. In silico 
analysis of transcribed polymorphisms in patient metastases for prediction 
of therapy response. Table S9. Comparison of commonly mutated genes 
in CRC and its metastases. Table S10. Matched predictive biomarkers of 
respective drug treatment. Table S11. Matched predictive sequence vari‑
ants for treatment response in pmCRC. Table S12. Validation of improved 
response of pmCRC models to combination therapy with PARP inhibitors.
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